Standardization. Synapsa® is standardized to contain a minimum of 55% bacosides, the active compounds found in Bacopa monnieri. This ensures that each dose of Synapsa contains a consistent amount of the active ingredients, making it easier to determine the appropriate dosage.

Patented extraction process. The extraction process used to produce Synapsa® is patented, ensuring a high level of purity and consistency. The patented extraction process also allows for the removal of unwanted compounds, reducing the risk of adverse effects.

Clinical studies. As previously mentioned, Synapsa® has been clinically studied for over 30 years, demonstrating its safety and efficacy. The clinical studies on Synapsa® have been published in peer-reviewed journals, making the evidence-based benefits of Synapsa® widely accessible.